- Home
- YALA vs PCRX Comparison
YALA vs PCRX Comparison
Compare YALA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | PCRX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | YALA | PCRX |
|---|---|---|
| Price | $7.17 | $20.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.33 |
| AVG Volume (30 Days) | 345.1K | ★ 1.0M |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.79 | N/A |
| EPS | ★ 0.82 | 0.47 |
| Revenue | $348,904,940.00 | ★ $716,791,000.00 |
| Revenue This Year | $3.07 | $6.21 |
| Revenue Next Year | $11.99 | $8.26 |
| P/E Ratio | ★ $8.69 | $44.07 |
| Revenue Growth | ★ 5.80 | 3.14 |
| 52 Week Low | $3.83 | $18.80 |
| 52 Week High | $9.29 | $27.64 |
Technical Indicators
Market Signals| Indicator | YALA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 36.78 |
| Support Level | $6.46 | $18.80 |
| Resistance Level | $7.40 | $21.12 |
| Average True Range (ATR) | 0.25 | 1.27 |
| MACD | 0.01 | -0.42 |
| Stochastic Oscillator | 73.54 | 25.00 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.